The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 31-38

  Daly, Ella J ^a   Trivedi, Madhukar H ^a   Fava, Maurizio ^b   Shelton, Richard ^c   Wisniewski, Stephen R ^d   Morris, David W ^a   Stegman, Diane ^a   Preskorn, Sheldon H ^e   Rush, A John ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

adverse events; major depressive disorder; remission

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ANXIETY DISORDER; APATHY; ARTICLE; BLURRED VISION; BREATHING DISORDER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; FATIGUE; FLUID RETENTION; HAIR LOSS; HEADACHE; HEART BEAT; HOT FLUSH; HUMAN; HYPERSALIVATION; INCREASED APPETITE; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEMORY DISORDER; MENSTRUATION DISORDER; MENTAL CONCENTRATION; MICTURITION DISORDER; MUSCLE CRAMP; MUSCLE TWITCH; MUSCLE WEAKNESS; NAUSEA; NOSE CONGESTION; ORGASM DISORDER; OTOTOXICITY; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; RASH; RATING SCALE; REMISSION; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN BRUISING; SLEEP DISORDER; SLURRED SPEECH; STOMACH DISCOMFORT; SWEATING; SYMPTOM; SYSTEMATIC ASSESSMENT FOR TREATMENT EMERGENT EVENTS SYSTEMATIC INQUIRY; TASTE DISORDER; THORAX PAIN; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SUICIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651338227     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318205e17b     Document Type: Article

References (46)

1. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
2. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
3. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol. 1994;8:48-53.
4. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25:2289-2304.
5. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
6. Meijer WE, Heerdink ER, Van Eijk JT, et al. Adverse events in users of sertraline: results from an observational study in psychiatric practice in the Netherlands. Pharmacoepidemiol Drug Saf. 2002;11:655-662.
7. Beasley CM Jr, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000;22: 1319-1330.
8. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160:1830-1835.
9. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54:879-883.
10. Popp J, Leucht S, Heres S, et al. Serotonin transporter polymorphisms and side effects in antidepressant therapyVa pilot study. Pharmacogenomics. 2006;7:159-166.
11. Smits K, Smits L, Peeters F, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 2007;22:137-143.
12. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61:1163-1169.
13. Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433-441.
14. Morris DW, Trivedi MH, Husain MM, et al. Indicators of pretreatment suicidal ideation in adults with major depressive disorder. Acta Psychiatr Scand. 2010;121:480-484.
15. Warden D, Trivedi MH, Wisniewski SR, et al. Identifying risk for attrition during treatment for depression. Psychother Psychosom. 2009;78:372-379.
16. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494, x.
17. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142. (Pubitemid 38230109)
18. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
19. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001;58:787-794.
20. Zimmerman M, Mattia JI. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry. 2001;42:175-189. (Pubitemid 32410920)
21. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32:2479-2489.
22. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(suppl 2): S61-S71.
23. Rush AJ, Carmody TJ, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res. 2000;9:45-59.
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression [published correction appears in Biol Psychiatry 2003;54:585]. Biol Psychiatry. 2003;54:573-583.
25. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73-82.
26. Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71-79.
27. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343-381.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
29. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
30. Miller IW, Norman WH, Bishop SB, et al. The Modified Scale for Suicidal Ideation: reliability and validity. J Consult Clin Psychol. 1986;54:724-725.
31. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
32. Altman EG, Hedeker DR, Janicak PG, et al. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry. 1994;36:124-134.
33. Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep. 1965;16:547-554.
34. Osman A, Gutierrez PM, Kopper BA, et al. The positive and negative suicide ideation inventory: development and validation. Psychol Rep. 1998;82:783-793.
35. Kabacoff RI, Segal DL, Hersen M, et al. Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. J Anxiety Disord. 1997;11:33-47.
36. Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49:156-163.
37. National Institute of Mental Health. Systematic Assessment of Side Effects. Rockville, MD: NIMH; 1986.
38. Jacobson AF, Goldstein BJ, Dominguez RA, et al. Interrater agreement and intraclass reliability measures of SAFTEE in psychopharmacologic clinical trials. Psychopharmacol Bull. 1986;22:382-388.
39. Rabkin JG, Markowitz JS. Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol Bull. 1986;22:389-396.
40. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18:65-87.
41. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477-486.
42. US Census Bureau. American Community Survey. Available at: http://www.census.gov/acs/www/2006. Accessed January 5, 2006.
43. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf. 1997;6:235-246.
44. Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83:53-63.
45. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry. 2001;62:18-24.
46. Warden D, Trivedi MH, Wisniewski SR, et al. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol. 2010;30:259-266.